

### **SPECIFICATION**

**Please amend the ABSTRACT as follows:**

Embodiments of the present invention include compositions and pharmaceutical compositions comprising citrulline and Hmg-CoA reductase inhibitors. Further embodiments relate to the use of such compositions to treat subjects and stimulating nitric oxide synthase. ~~Vessels are treated with a mixture of L-arginine and an agent which enhances the biotransformation of L-arginine into NO. The incidents associated with restenosis are expected to be substantially reduced and prevented providing for a reduced incidence of restenosis as a result of the injury.~~

**Please amend paragraph [0001] as follows:**

~~RELATED APPLICATION DATA-CROSS-REFERNCES TO RELATED APPLICATIONS~~

[0001] This application is a continuation application of U.S. Serial No 10/207,399, filed on July 29, 2002, which is a continuation application of U.S. Serial No. 09/293,392 filed April 16, 1999, now U.S. Patent No. 6,425,881, which is a continuation-in-part application of U.S. Serial No. 09/226,580 filed January 7, 1999, now U.S. Patent No. 6,239,172, which is a continuation-in-part application of U.S. Serial No. 09/833,842 filed April 10, 1997, now U.S. Patent No. 5,968,983-which is a continuation -in-part application of U.S. Serial No. 08/693,882 filed August 5, 1996, now U.S. Patent No. 5,767,160 dated August 6, 1996, which is a continuation-in-part application of U.S. Serial No. 08/321,051 filed October 5, 1994, now U.S. Patent No. 5,543,430 dated June 16, 1998.